At the time of acquisition, Nicholas Laboratories was ranked 48th among the pharmaceutical companies in India. From FY1988-FY2010, the Company entered into a series of value accretive M&As, JVs and alliances, and derived synergies by bringing efficiencies in distribution and cost reduction. Through various organic and inorganic initiatives, it transformed to become 3rd largest pharma company of India. During the period, the revenue and net profits grew at a CAGR of 28% and 34%, respectively.
During FY2011, the Company sold its Domestic Formulations business to Abbott for a total consideration of US$ 3.8 billion. At 9x FY2010 Sales and 30x FY2010 EBITDA, the transaction established a new benchmark for valuation in global pharmaceutical space
R&D based out of
Note: 1. Revenue for Domestic Formulations and Diagnostic Services have been taken for FY2010
Market Capitalisation as on March 31, 2011
Capital Returned till March 31, 2011
Total value created till March 31, 2011